Xencor, Inc.

Jonathan Zalevsky

John R Desjarlais

Gregory L Moore

Matthew J Bernett

Arthur J Chirino

Duc-Hanh Thi Nguyen

Sergei A Ezhevsky

Darian Cash

David Szymkowski

Paul Michael Steed

Anton Filikov

Bassil I Dahiyat

Umesh Muchhal

Shannon Marshall

David F Carmichael

Malu Lourdes G Tansey

A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.

Method of treatment using adiponectin variants

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Adiponectin variants

The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.

Treatment of TNF-&#x3b1; related disorders with TNF-&#x3b1; variant proteins

A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4&#xb0; C. for one week in 10 mM PO, 150 mM NaCl buffer.

Pharmaceutical compositions of adiponectin variants and methods of storage

The invention relates to a pharmaceutical composition comprising a variant TNF-&#x3b1; protein that inhibits the activity of soluble TNF-&#x3b1; while substantially maintaining the activity of transmembrane TNF-&#x3b1; a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.

Pharmaceutical compositions for the treatment of TNF-&#x3b1; related disorders

The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

PEGylated TNF-&#x3b1; variant proteins

Methods for rational pegylation of proteins

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Globular adiponectin variants

The invention relates to variants of BMP-7 with improved properties and methods for their use.

BMP-7 variants with improved properties

The invention relates to novel proteins with TNF-&#x3b1; antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-&#x3b1; related disorders.

Growing community of inventors

Riverside, CA, United States of America

Jonathan Zalevsky